2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow EC20: new trials by email Literature Review of EC20 trials Research Report on EC20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Endocyte | 203 | 2011-03-01 | 2021-04-01 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer | Phase 2 | Completed | Endocyte | 162 | 2008-09-01 | 2015-01-07 |
Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Endocyte (2)